PMID- 33221193
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 32
IP  - 2
DP  - 2021 Feb
TI  - Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant 
      Propranolol-Resistant Infantile Hemangiomas in the Parotid Region.
PG  - 293-298
LID - S1051-0443(20)30862-9 [pii]
LID - 10.1016/j.jvir.2020.09.029 [doi]
AB  - PURPOSE: To report the effectiveness and safety of transcatheter arterial 
      sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas 
      that did not respond appreciably to propranolol. MATERIALS AND METHODS: A total 
      of 21 infants (12 male and 9 female) with large propranolol-resistant infantile 
      hemangiomas in the parotid region were enrolled in this study. During TASE, the 
      feeding arteries of the lesions were embolized using pingyangmycin-lipiodol 
      emulsion and polyvinyl alcohol particles (300-500 mum) to reduce the blood flow 
      rate. All children were followed up as outpatients at 2 weeks and monthly 
      thereafter. The curative effect was evaluated at the 1- and 3-month follow-up 
      visits. RESULTS: Nine lesions were located on the right side of the parotid 
      gland, whereas 12 were located on the left side. The feeding arteries in all 
      patients originated from branches of the external carotid artery. TASE was 
      technically successful in all patients. The mean (+/- SD) maximal diameter of the 
      hemangiomas significantly decreased from 6.50 cm +/- 2.28 before treatment to 3.56 
      cm +/- 1.84 at 1 month after TASE (P <. 05). Three months after TASE, the mean 
      maximal diameter further significantly decreased to 1.94 cm +/- 1.58 (P <. 05). 
      During the follow-up period, 16 cases were rated as excellent and 5 as good; no 
      recurrence or serious complications were noted. Minor side effects, such as 
      slight pain, mild fever, and tissue swelling, were observed. CONCLUSIONS: TASE 
      significantly decreased the size of the parotid hemangiomas with minor side 
      effects during a short follow-up period.
CI  - Copyright (c) 2020 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Wu, Changhua
AU  - Wu C
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Song, Dan
AU  - Song D
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Li, Jing
AU  - Li J
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Sun, Jiali
AU  - Sun J
AD  - Department of Vascular Anomalies and Interventional Radiology, Qilu 
      Children'sHospital of Shandong University, Room 23976, Jingshi Road, Jinan City, 
      Shandong prov. CN 250022.
FAU - Zhang, Yunkui
AU  - Zhang Y
AD  - Department of Stomatology, Qilu Children'sHospital of Shandong University, Room 
      23976, Jingshi Road, Jinan City, Shandong prov. CN 250022. Electronic address: 
      zhangyunkui2019@126.com.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Sclerosing Solutions)
RN  - 11056-06-7 (Bleomycin)
RN  - 5DY91Y7601 (bleomycetin)
RN  - 8008-53-5 (Ethiodized Oil)
RN  - 9002-89-5 (Polyvinyl Alcohol)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Bleomycin/administration & dosage/analogs & derivatives
MH  - *Drug Resistance, Neoplasm
MH  - *Embolization, Therapeutic/adverse effects
MH  - Ethiodized Oil/administration & dosage
MH  - Female
MH  - Hemangioma/diagnostic imaging/pathology/*therapy
MH  - Humans
MH  - Infant
MH  - Male
MH  - Parotid Neoplasms/diagnostic imaging/pathology/*therapy
MH  - Polyvinyl Alcohol/administration & dosage
MH  - Propranolol/*therapeutic use
MH  - Sclerosing Solutions/administration & dosage
MH  - *Sclerotherapy/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Burden
EDAT- 2020/11/23 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/11/22 20:32
PHST- 2020/02/12 00:00 [received]
PHST- 2020/09/22 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/11/23 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
PHST- 2020/11/22 20:32 [entrez]
AID - S1051-0443(20)30862-9 [pii]
AID - 10.1016/j.jvir.2020.09.029 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2021 Feb;32(2):293-298. doi: 10.1016/j.jvir.2020.09.029. 
      Epub 2020 Nov 18.